JPS61106511A - 抗真菌性医薬組成物 - Google Patents
抗真菌性医薬組成物Info
- Publication number
- JPS61106511A JPS61106511A JP60155011A JP15501185A JPS61106511A JP S61106511 A JPS61106511 A JP S61106511A JP 60155011 A JP60155011 A JP 60155011A JP 15501185 A JP15501185 A JP 15501185A JP S61106511 A JPS61106511 A JP S61106511A
- Authority
- JP
- Japan
- Prior art keywords
- group
- acid
- formula
- item
- bile acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 9
- 230000001857 anti-mycotic effect Effects 0.000 title 1
- 239000002543 antimycotic Substances 0.000 title 1
- 239000003613 bile acid Substances 0.000 claims description 34
- 239000002253 acid Chemical group 0.000 claims description 21
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 19
- 241000222122 Candida albicans Species 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010007134 Candida infections Diseases 0.000 claims description 5
- 201000003984 candidiasis Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000010410 dusting Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 2
- 239000007963 capsule composition Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 8
- 159000000000 sodium salts Chemical class 0.000 description 8
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 6
- 239000004380 Cholic acid Substances 0.000 description 6
- 229960002471 cholic acid Drugs 0.000 description 6
- 235000019416 cholic acid Nutrition 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 6
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 5
- 230000001032 anti-candidal effect Effects 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 4
- 229960002509 miconazole Drugs 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical group OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 244000235992 Acalypha lanceolata Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241001006154 Phara Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101150094640 Siae gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- NGPGDYLVALNKEG-UHFFFAOYSA-N azanium;azane;2,3,4-trihydroxy-4-oxobutanoate Chemical compound [NH4+].[NH4+].[O-]C(=O)C(O)C(O)C([O-])=O NGPGDYLVALNKEG-UHFFFAOYSA-N 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229940009025 chenodeoxycholate Drugs 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000002245 gallstone dissolution Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848417895A GB8417895D0 (en) | 1984-07-13 | 1984-07-13 | Pharmaceutical anti-fungal composition |
| GB8417895 | 1984-07-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61106511A true JPS61106511A (ja) | 1986-05-24 |
| JPH0478616B2 JPH0478616B2 (enrdf_load_stackoverflow) | 1992-12-11 |
Family
ID=10563846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60155011A Granted JPS61106511A (ja) | 1984-07-13 | 1985-07-13 | 抗真菌性医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4681876A (enrdf_load_stackoverflow) |
| EP (1) | EP0168229B1 (enrdf_load_stackoverflow) |
| JP (1) | JPS61106511A (enrdf_load_stackoverflow) |
| DE (1) | DE3587577T2 (enrdf_load_stackoverflow) |
| GB (2) | GB8417895D0 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500506A (ja) * | 2018-09-25 | 2022-01-04 | イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッドYichang Humanwell Pharmaceutical Co., Ltd | 免疫調節薬としてのｔｇｒ５シグナル伝達のレギュレーター |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565586A (en) * | 1984-06-22 | 1986-01-21 | Brush Wellman Inc. | Processing of copper alloys |
| US4892868A (en) * | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
| US4866044A (en) * | 1985-07-09 | 1989-09-12 | Takeda Chemical Industries, Ltd. | Solubilized composition of poorly-soluble pharmaceutical product |
| DE3704907A1 (de) * | 1987-02-17 | 1988-08-25 | Bayer Ag | Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden |
| GB8706313D0 (en) * | 1987-03-17 | 1987-04-23 | Health Lab Service Board | Treatment & prevention of viral infections |
| US4921838A (en) * | 1987-06-16 | 1990-05-01 | Trustees Of Boston University | Angiogenic and blood perfusion inducing properties of amphiphilic compounds |
| WO1990003172A2 (en) * | 1988-09-20 | 1990-04-05 | Fisons Plc | Bile acids for treatment of viral infections |
| GB8910364D0 (en) * | 1989-05-05 | 1989-06-21 | Nat Res Dev | Anti-fungal compounds |
| CA2033725C (en) * | 1990-01-24 | 2001-05-29 | Folker Pittrof | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
| US5079240A (en) * | 1990-03-15 | 1992-01-07 | The Regents Of The University Of California | Synthetic conjugated bile acid and method of use thereof |
| GB9010087D0 (en) * | 1990-05-04 | 1990-06-27 | Nat Res Dev | Anti-fungal compounds |
| ES2027527A6 (es) * | 1990-12-17 | 1992-06-01 | Andromaco Lab | Procedimiento para la obtencion de polimeros dotados de actividad antiviral. |
| CH680704A5 (enrdf_load_stackoverflow) * | 1991-05-15 | 1992-10-30 | Medichemie Ag | |
| IT1255450B (it) * | 1992-06-30 | 1995-10-31 | Montefarmaco Spa | Uso di acidi biliari come agenti antivirali |
| US5646316A (en) * | 1994-04-08 | 1997-07-08 | Osteoarthritis Sciences, Inc. | Bile acid inhibitors of metalloproteinase enzymes |
| EP0720854A1 (de) * | 1995-01-04 | 1996-07-10 | Medichemie Ag | Verwendung von Gallensäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen der Haut |
| FR2760362B1 (fr) | 1997-03-10 | 2000-08-11 | Vitasterol | Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles |
| US6767904B2 (en) | 1998-03-06 | 2004-07-27 | Bringham Young University | Steroid derived antibiotics |
| US6350738B1 (en) | 1998-03-06 | 2002-02-26 | Brigham Young University | Steroid derived antibiotics |
| US7303768B2 (en) | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| PT1113785E (pt) | 1998-07-24 | 2005-08-31 | Seo Hong Yoo | Solucoes aquosas limpidas de acidos biliares |
| US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| AU3668501A (en) * | 2000-02-04 | 2001-08-14 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| KR20030003952A (ko) * | 2001-07-04 | 2003-01-14 | 주식회사 엘지생활건강 | 염증성 피부질환의 예방 및 치료용 조성물 |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
| US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| ES2660172T3 (es) | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Composición inyectable que comprende desoxicolato de sodio |
| ES2339790T3 (es) * | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | Efecto neuroprotector de udca solubilizado en modelo isquemico focal. |
| US20060074057A1 (en) * | 2004-10-04 | 2006-04-06 | Eric Marchewitz | Use of chenodeoxycholic acid for reducing adipose tissue |
| EP1809330B1 (en) * | 2004-10-15 | 2011-04-27 | Seo Hong Yoo | Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| US20070071706A1 (en) * | 2005-09-28 | 2007-03-29 | Filiberto Zadini | Lipodissolving dermatological topical preparation |
| JOP20180077A1 (ar) | 2007-06-19 | 2019-01-30 | Kythera Biopharmaceuticals Inc | تركيبات وطرق لحمض صفراوي تخليقي |
| US8242294B2 (en) | 2007-06-19 | 2012-08-14 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| US20080318870A1 (en) | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
| US9127036B2 (en) | 2010-08-12 | 2015-09-08 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| WO2012047495A2 (en) * | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
| US20120237492A1 (en) | 2011-02-18 | 2012-09-20 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
| US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
| KR101548955B1 (ko) * | 2013-08-26 | 2015-09-02 | (주)샤페론 | Gpcr19 작용제를 유효성분으로 함유하는 아토피 예방 또는 치료용 조성물 |
| WO2018039087A1 (en) * | 2016-08-20 | 2018-03-01 | Gregg John Malcolm Hall | Antimicrobial drug methods of use & therapeutic compositions |
| US20200038323A1 (en) * | 2017-03-31 | 2020-02-06 | Rowan University | Optically clear, in-situ forming biodegradable nano-carriers for ocular therapy, and methods using same |
| DE102020006049A1 (de) | 2020-10-02 | 2022-04-07 | Radim Vlcek | Desoxycholsäure sowie deren Verbindungen zur Verwendung bei der Behandlung von Erkrankungen |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL79885C (enrdf_load_stackoverflow) * | 1950-04-14 | |||
| GB848333A (en) * | 1956-11-27 | 1960-09-14 | Matthew Hoare | Healing ointment |
| US3860712A (en) * | 1973-04-16 | 1975-01-14 | Sterling Drug Inc | Composition and method for treatment of acne or seborrhea |
| US4164573A (en) * | 1975-06-13 | 1979-08-14 | Galinsky Alvin M | Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal |
| GB1563311A (en) * | 1975-09-26 | 1980-03-26 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition of insulin for rectal use |
| JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
| EP0037943B1 (en) * | 1980-03-31 | 1985-08-14 | Teijin Limited | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom |
| IT1167478B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido ursodesossicolico |
| PH18373A (en) * | 1982-02-02 | 1985-06-13 | Unilever Nv | Skin treatment composition |
| IL68769A (en) * | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
-
1984
- 1984-07-13 GB GB848417895A patent/GB8417895D0/en active Pending
-
1985
- 1985-07-05 EP EP85304830A patent/EP0168229B1/en not_active Expired - Lifetime
- 1985-07-05 GB GB08517065A patent/GB2161380B/en not_active Expired
- 1985-07-05 DE DE85304830T patent/DE3587577T2/de not_active Expired - Fee Related
- 1985-07-13 JP JP60155011A patent/JPS61106511A/ja active Granted
- 1985-07-15 US US06/755,016 patent/US4681876A/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500506A (ja) * | 2018-09-25 | 2022-01-04 | イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッドYichang Humanwell Pharmaceutical Co., Ltd | 免疫調節薬としてのｔｇｒ５シグナル伝達のレギュレーター |
Also Published As
| Publication number | Publication date |
|---|---|
| US4681876A (en) | 1987-07-21 |
| GB2161380A (en) | 1986-01-15 |
| EP0168229A2 (en) | 1986-01-15 |
| JPH0478616B2 (enrdf_load_stackoverflow) | 1992-12-11 |
| DE3587577T2 (de) | 1994-01-13 |
| GB2161380B (en) | 1987-10-07 |
| GB8517065D0 (en) | 1985-08-14 |
| GB8417895D0 (en) | 1984-08-15 |
| EP0168229A3 (en) | 1990-07-18 |
| EP0168229B1 (en) | 1993-09-15 |
| DE3587577D1 (de) | 1993-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61106511A (ja) | 抗真菌性医薬組成物 | |
| JP3777499B2 (ja) | 抗真菌組成物 | |
| EP2266626B1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
| EP0621263A2 (en) | External anti-inflammatory and analgesic plaster preparation | |
| JPS6036423A (ja) | Ｎ−（２−ヒドロキシエチル）ピロリドンを含有する浸透局所製薬組成物 | |
| JP2004529935A (ja) | 外陰部膣炎と膣症とを治療するための抗真菌剤を含む組成物 | |
| JP2002047186A (ja) | 眼部前段および眼部表面の免疫関連性疾病用治療薬物 | |
| JPH08501317A (ja) | 抗菌性インターフェロン誘発性医薬品 | |
| JPH09165344A (ja) | 膣用固形医薬品組成物 | |
| JPS604802B2 (ja) | 制癌剤 | |
| US20060194829A1 (en) | Therapeutic materials and methods | |
| CN115515599A (zh) | 化合物在真菌感染的治疗中的用途 | |
| LT4441B (lt) | Antigliukokortikoidinis vaistinis preparatas | |
| AU718461B2 (en) | Wound healing accelerators | |
| RU2120305C1 (ru) | Фармацевтический состав, обладающий противогрибковой активностью, и способ его получения | |
| EP0470995B1 (en) | Use of steroidal compounds as anti-fungal agents | |
| EP0820289B1 (de) | Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern | |
| US7704976B2 (en) | Use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
| CA2102518A1 (en) | Antifungal agents | |
| JPH09176014A (ja) | 抗真菌性外用組成物 | |
| EP1667622A2 (en) | Water dispersible film | |
| US3322627A (en) | Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor | |
| JP2000119186A (ja) | スクラルファート含有局所投与用医薬組成物 | |
| RU2805930C1 (ru) | Использование соединений при лечении грибковых инфекций | |
| US4895859A (en) | Anti-infective methods and compositions |